Development and validation of a methotrexate adherence assay
Open Access
- 1 September 2019
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 78 (9) , 1192-1197
Abstract
Background The first-line therapy for rheumatoid arthritis (RA) is weekly oral methotrexate (MTX) at low dosages (7.5–25 mg/week). However, ~40% of patients are non-adherent which may explain why some do not respond and need to start more expensive biological therapies. To monitor adherence more accurately and develop strategies to improve it, a validated objective MTX adherence test is required. Objective To develop and validate the diagnostic accuracy of a novel MTX adherence assay using high-performance liquid chromatography–selected reaction monitoring– mass spectrometry (HPLC-SRM-MS) based biochemical analysis of drug levels. Methods 20 patients with RA underwent MTX pharmacokinetic assessment using HPLC-SRM-MS MTX plasma concentration analysis over a 6-day period. Directly observed therapy was the reference standard. Pharmacokinetic model validation was performed using independent plasma samples from real-world patients (n=50) with self-reported times of drug administration. Following assay optimisation, the sensitivity of the assay to detect adherence was established using samples from an observational cohort study (n=138). Results A two-compartment pharmacokinetic model was developed and validated. Simulations described the sensitivity required for MTX detection over 7 days; subsequent assay optimisation and retesting of samples confirmed that all patients were correctly identified as MTX adherers. Using real-world samples, the assays sensitivity was 95%. Conclusion Non-adherence to MTX is common and can have a significant effect on disease activity. HPLC-SRM-MS plasma analysis accurately detects MTX adherence. The validated objective test could easily be used in clinic to identify patients requiring adherence support.Keywords
Funding Information
- Medical Research Council (G1000417/94909)
- Medical Research Council and Engineering and Physical Sciences Research Council (MR/N00583X/1)
- Versus Arthritis (20380, 21754)
This publication has 28 references indexed in Scilit:
- Electronic Monitoring of Oral Therapies in Ethnically Diverse and Economically Disadvantaged Patients With Rheumatoid Arthritis: Consequences of Low AdherenceArthritis & Rheumatism, 2013
- Development and validation of a liquid chromatography–tandem mass spectrometry assay for hair analysis of atomoxetine and its metabolites: Application in clinical practiceForensic Science International, 2012
- Population Pharmacokinetics of Telapristone (CDB-4124) and its Active Monodemethylated Metabolite CDB-4453, with a Mixture Model for Total ClearanceThe AAPS Journal, 2011
- Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practiceArthritis Care & Research, 2011
- Inadequate Therapy Behavior Is Associated to Disease Flares in Patients With Rheumatoid Arthritis Who Have Achieved Remission With Disease-Modifying Antirheumatic DrugsThe American Journal of the Medical Sciences, 2010
- Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritisArthritis & Rheumatism, 2008
- Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2007
- Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1994
- Effect of food on the bioavailability of low‐dose methotrexate in patients with rheumatoid arthritisArthritis & Rheumatism, 1992
- Pharmacokinetics of Low-Dose Methotrexate in Rheumatoid Arthritis PatientsJournal of Pharmaceutical Sciences, 1989